1. In vitro HIV-specific CTL activity from HIV-seropositive individuals is augmented by interleukin-12 (IL-12)
- Author
-
Robyn L. Tideman, Graeme J. Stewart, David A. Fulcher, Don Packham, Elizabeth M. Benson, Janett D. Clarkson, Tong Liang, Rosemary A. Ffrench, and Judy Young
- Subjects
Interleukin 2 ,Adult ,Male ,Cellular immunity ,medicine.medical_treatment ,Immunology ,Biology ,Peripheral blood mononuclear cell ,T-Lymphocytes, Regulatory ,Virology ,HIV Seronegativity ,HIV Seropositivity ,medicine ,Humans ,Cells, Cultured ,virus diseases ,hemic and immune systems ,Middle Aged ,biology.organism_classification ,Interleukin-12 ,Recombinant Proteins ,CTL ,Infectious Diseases ,Cytokine ,Lentivirus ,Interleukin 12 ,HIV-1 ,Leukocytes, Mononuclear ,Female ,CD8 ,medicine.drug ,T-Lymphocytes, Cytotoxic - Abstract
IL-12 production is reduced in HIV infection, and recombinant human IL-12 (rhIL-12) augments in vitro HIV-specific proliferative responses in PBMC from HIV-seropositive individuals. To determine whether rhIL12 could also augment HIV-specific CTL responses we studied 41 HIV-seropositive individuals. Recombinant hIL-12 increased the detectable in vitro HIV-specific CD8 CTL activity of PBMC taken from HIV-seropositive individuals with CD4 counts500 cells/microl and from some individuals with lower CD4 counts. IL-12 increased cell recovery in cultures of PBMC from HIV-seropositive individuals with CD4 counts500 cells/microl and also increased the precursor CTL frequency. However, the increase in HIV-specific CTL activity was not due to IL-2 or IFN-gamma production or an increase in the number of cells with surface markers characteristic of CTL effector cells. This study demonstrates that rhIL-12 augments in vitro HIV-specific CTL activity and provides evidence to justify further investigation within clinical trials of this cytokine in HIV infection.
- Published
- 2001